Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom.
| Revenue (Most Recent Fiscal Year) | $3.13B |
| Net Income (Most Recent Fiscal Year) | $359.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 12.43 |
| Pre-Tax Margin (Trailing 12 Months) | 14.55% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.28 |
| Inventory Turnover (Trailing 12 Months) | 1.78 |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 221.89M |
| Free Float | -- |
| Market Capitalization | $6.15B |
| Average Volume (Last 20 Days) | 13.20 |
| Beta (Past 60 Months) | 0.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.96 |
| Dividend Yield (Based on Last Quarter) | 3.46% |